Full Text View
Tabular View
No Study Results Posted
Related Studies
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
This study has been completed.
Study NCT00243035   Information provided by National Cancer Institute (NCI)

First Received on October 20, 2005.   Last Updated on January 22, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Additional conditions recognized in this trial
Multiple Myeloma
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
bortezomib
tipifarnib
laboratory biomarker analysis
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services